NYSEMKT: CCELCryo Cell International Inc Stock
$7.87+0.15 (+1.94%)
Updated Apr 24, 2024
CCEL Price
$7.87
Fair Value Price
N/A
Market Cap
$63.78M
52 Week Low
$3.67
52 Week High
$8.15
P/E
-6.78x
P/B
-6.17x
P/S
1.37x
PEG
N/A
Dividend Yield
N/A
Revenue
$31.37M
Earnings
-$9.73M
Gross Margin
72.8%
Operating Margin
-40.67%
Profit Margin
-31%
Debt to Equity
-6.97
Operating Cash Flow
$7M
Beta
0.16
Next Earnings
N/A
Ex-Dividend
N/A
Next Dividend
N/A
CCEL Overview
Cryo-Cell International, Inc. engages in the cellular processing and cryogenic cellular storage with a focus on the collection and preservation of umbilical cord blood stem cells for family use. It provides cord tissue service that stores a section of the umbilical cord tissue, a source of mesenchymal stem cells that are used in regenerative medicine to treat a range of conditions, including heart, kidney, ALS, wound healing, and auto-immune diseases. The company also manufactures and sells PrepaCyte CB processing system, a technology used to process umbilical cord blood stem cells. It stores approximately 500,000 cord blood and cord tissue stem cells worldwide. The company markets its cord blood stem cell preservation services directly to expectant parents, as well as by distributing information through obstetricians, pediatricians, childbirth educators, certified nurse-midwives, and other related healthcare professionals. Cryo-Cell International, Inc. was founded in 1989 and is headquartered in Oldsmar, Florida.
Zen Score
–
Industry Average (30)
You've viewed Zen Score for 10/10 free stocks. Upgrade to Premium to see how CCEL scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.
Due Diligence Checks
CCEL is unprofitable, so we are unable to calculate its intrinsic value according to an updated version of Benjamin Graham's Formula from "The Intelligent Investor"
Below Benjamin Graham Formula Value Valuation
CCEL is unprofitable, so we are unable to assess its PEG ratio
PEG Value Valuation
CCEL's cash and short-term investments... subscribe to Premium to read more.
Interest Coverage Financials
There are 30 more CCEL due diligence checks available for Premium users.
Be the first to know about important CCEL news, forecast changes, insider trades & much more!
CCEL News
Valuation
CCEL price to earnings (PE)
For valuing profitable companies with steady earnings
Company
-6.78x
Industry
-2.13x
Market
41.27x
CCEL price to book (PB)
For valuing companies that are loss-making or have lots of physical asset
Company
-6.17x
Industry
4.61x
CCEL's financial health
Profit margin
Revenue
$7.9M
Net Income
$556.2k
Profit Margin
7.1%
CCEL's cash and short-term investments... subscribe to Premium to read more.
Interest Coverage Financials
CCEL's profit margin has decreased... subscribe to Premium to read more.
Profit Margin Growth Financials
Assets to liabilities
Assets
$61.7M
Liabilities
$72.0M
Debt to equity
-6.97
CCEL's short-term liabilities ($19.37M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
CCEL's long-term liabilities ($52.68M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
CCEL's debt relative to shareholder... subscribe to Premium to read more.
Shrinking Debt Financials
CCEL's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials
Cash flow
Operating
-$356.9k
Investing
-$341.0k
Financing
$539.0k
CCEL's cash and short-term investments... subscribe to Premium to read more.
Debt Coverage Financials
CCEL vs Medical Care Facility Stocks
Cryo Cell International Stock FAQ
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.